Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer
Authors:
- Rituraj UpadhyayRURituraj Upadhyay
- Emile GogineniEGEmile Gogineni
- Glenis TocajGTGlenis Tocaj
- Sung J. MaSMSung J. Ma
- Marcelo BonomiMBMarcelo Bonomi
- Priyanka BhatejaPBPriyanka Bhateja
- David J. KonieczkowskiDKDavid J. Konieczkowski
- Sujith BaligaSBSujith Baliga
- Darrion L. MitchellDMDarrion L. Mitchell
- Sachin R. JhawarSJSachin R. Jhawar
- Simeng ZhuSZSimeng Zhu
- John C. GreculaJGJohn C. Grecula
Open Access
Abstract
Objectives: Patients with recurrent and metastatic head and neck cancer (HNC) have limited treatment options. ‘QuadShot’ (QS), a hypofractionated palliative radiotherapy regimen, can provide symptomatic relief and local control and may potentiate the effects of immune checkpoint inhibitors (ICIs). We compared outcomes of QS ± concurrent ICIs in the palliative treatment of HNC. Materials and Methods: We identified patients who received ≥three cycles of QS from 2017 to 2022 and excluded patients without post-treatment clinical evaluation or imaging. Outcomes for patients who received QS alone were compared to those treated with ICI concurrent with QS, defined as receipt of ICI within 4 weeks of QS. Results: Seventy patients were included, of whom 57% received concurrent ICI. Median age was 65.5 years (interquartile range [IQR]: 57.9–77.8), and 50% patients had received prior radiation to a median dose of 66 Gy (IQR: 60–70). Median follow-up was 8.8 months. Local control was significantly higher with concurrent ICIs (12-month: 85% vs. 63%, p = 0.038). Distant control (12-month: 56% vs. 63%, p = 0.629) and median overall survival (9.0 vs. 10.0 months, p = 0.850) were similar between the two groups. On multivariable analysis, concurrent ICI was a significant predictor of local control (HR for local failure: 0.238; 95% CI: 0.073–0.778; p = 0.018). Overall, 23% patients experienced grade 3 toxicities, which was similar between the two groups. Conclusions: The combination of QS with concurrent ICIs was well tolerated and significantly improved local control compared to QS alone. The median OS of 9.4 months compares favorably to historical controls for patients with HNC treated with QS. This approach represents a promising treatment option for patients with HNC unsuited for curative-intent treatment and warrants prospective evaluation.Keywords
This publication has 37 references indexed in Scilit:
- LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)Annals of Oncology, 2022
- Utilization of the ‘QUAD SHOT’ for Palliating Malignancies of the Head and NeckInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- A Prospective Phase 2 Trial of Reirradiation With Stereotactic Body Radiation Therapy Plus Cetuximab in Patients With Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and NeckInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Palliative radiation therapy for head and neck cancer: Toward an optimal fractionation schemeHead & Neck, 2008
- Final report of RTOG 9610, a multi‐institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neckHead & Neck, 2007
- Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1994
- Phase I–II study of multiple daily fractions for palliation of advanced head and neck malignanciesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1993
- Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: Preliminary report of RTOG 8502International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989